An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge

Amy Palin, Anasuya Chattopadhyay, Steven Park, Guillaume Delmas, Rema Suresh, Svetlana Senina, David S. Perlin, John K. Rose

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

We have developed recombinant vesicular stomatitis virus (VSV) vectors expressing the Yersinia pestis lcrV gene. These vectors, given intranasally to mice, induced high antibody titers to the LcrV protein and protected against intranasal (pulmonary) challenge with Y. pestis. High-level protection was dependent on using an optimized VSV vector that expressed high levels of the LcrV protein from an lcrV gene placed in the first position in the VSV genome, followed by a single boost. This VSV-based vaccine vector system has potential as a plague vaccine protecting against virulent strains lacking the F1 protein.

Original languageEnglish (US)
Pages (from-to)741-750
Number of pages10
JournalVaccine
Volume25
Issue number4
DOIs
StatePublished - Jan 8 2007
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Keywords

  • Plague vaccine
  • Vesicular stomatitis virus
  • Yersinia pestis

Fingerprint

Dive into the research topics of 'An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge'. Together they form a unique fingerprint.

Cite this